Q32 Bio advances alopecia drug trial, raises $10.5M, cash runway into 2028

Q32 Bio reported progress in its Phase 2a SIGNAL-AA trial for bempikibart, an alopecia areata treatment, with 36-week data expected mid-2026. The company dosed the first patient in the open-label extension and raised $10.5 million through a registered direct offering, strengthening its finances. With $50.8 million cash on hand plus additional proceeds, Q32 Bio expects funding through the first half of 2028. These developments support continued clinical advancement and potential pivotal trials for bempikibart.